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Abstract 
The development of therapeutic resistance to targeted anticancer therapies remains a 
significant clinical problem, with intratumoral heterogeneity playing a key role. In this 
context, improving the therapeutic outcome through simultaneous targeting of multiple 
tumor cell subtypes within a heterogeneous tumor is a promising approach. Liposomes 
have emerged as useful drug carriers that can reduce systemic toxicity and increase drug 
delivery to the tumor site. While clinically-used liposomal drug formulations show 
marked therapeutic advantages over free drug formulations, ligand-functionalized 
liposome drug formulations that can target multiple tumor cell subtypes may further 
improve the therapeutic efficacy by facilitating drug delivery to a broader population of 
tumor cells making up the heterogeneous tumor tissue. Ligand-directed liposomes 
enable the so-called active targeting of cell receptors via surface-attached ligands that 
direct drug uptake into tumor cells or tumor-associated stromal cells, and so can 
increase the selectivity of drug delivery. Despite promising preclinical results 
demonstrating improved targeting and anti-tumor effects of ligand-directed liposomes, 
there has been limited translation of this approach to the clinic. Key challenges for 
translation include the lack of established methods to scale up production and 
comprehensively characterize ligand-functionalized liposome formulations, and the 
inadequate recapitulation of in vivo tumors in the preclinical models currently used to 
evaluate their performance. Herein, we discuss the utility of recent ligand-directed 
liposome approaches, with a focus on dual-ligand liposomes, for the treatment of solid 
tumors and examine the drawbacks limiting their progression to clinical adoption. 
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Glossary of Key Terms 
Non-ligand modified liposomes Liposomes without surface-bound targeting ligands 
or modalities; efficacy is thought to be predominately 
achieved via the enhanced permeability and retention 
(EPR) effect 
Passively-targeted liposomes Non-functionalized liposomes that accumulate at the 
tumor site via the EPR effect 
Actively-targeted liposomes Liposomes with one or more surface-bound 
modalities (ligands) enabling binding to target cells 
to direct liposome uptake; encompasses single-
ligand, dual-ligand and multi- ligand liposomes 
Single- ligand liposomes Liposomes with a single surface-bound targeting 
ligand or modality for targeting to a specific cell 
surface receptor 
Dual-ligand liposomes Liposomes with two different surface-bound ligands 
or modalities for targeting to two different cell 
surface receptors 
Dual-functionalized liposomes Liposomes with two different functions for cell 
targeting; may or may not include a ligand/modality 
Enhanced permeability and 
retention (EPR) effect 
The permeation and retention of particles less than 
380-780 nm in size into the tumor interstitial space 
due to highly porous tumor vasculature and poor 
lymphatic drainage from the tumor site 
 
In this review, the key aspects of both inter- and intratumoral heterogeneity, and the 
rationale for using ligand-directed liposomes in tumor targeting will be described, 
before highlighting current research using dual-ligand directed liposome approaches 
that aim to address tumor heterogeneity. This review will then explore some of the 
reasons why, despite clinical adoption of non-ligand directed liposomes and promising 
preclinical findings for ligand-directed liposomes, ligand-directed liposomes have not 
yet progressed to the clinic. Finally, this review will outline essential areas for future 
research that will allow for improved formulation and preclinical evaluation of 
therapeutic liposomes in order to facilitate the clinical translation of ligand-
functionalized liposomes in the context of cancer therapy. 
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Tumor Heterogeneity and Therapeutic Resistance 
The molecular classification of tumors and the associated identification of tumor 
biomarkers are highly useful in both prognosis and determining the most appropriate 
treatment course. Many important biomarkers and cellular pathways involved in tumor 
progression and metastasis have been identified (for example, the estrogen receptor 
(ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) status in breast cancer) and assist in the prediction of patient responses to 
hormone, chemo-, immuno- and molecular targeted therapies, determination of 
mechanisms of therapeutic resistance (e.g. overexpression of MDR1), prediction of 
disease progression and likelihood of relapse [1, 2]. Overexpression of specific cell 
surface receptors by tumor cells may be exploited to directly target tumor cells using 
antibodies or smaller molecules, or to enable targeted delivery of cytotoxic compounds 
to tumor cells. Such targeted approaches enable more specific antitumor effects, 
potentially resulting in enhanced tumor cell kill and/or a reduction in off-target effects. 
Targeted therapies have been successfully used to treat some cancers – for example, the 
monoclonal antibodies trastuzumab and pertuzumab that target HER2 in the treatment 
of HER2-positive breast cancer [3]. 
Despite the therapeutic advantages of targeted therapies, the development of 
resistance to these therapies is now recognized as a significant clinical problem [4]. A 
leading example is the therapeutic resistance to imatinib (Gleevec), a tyrosine kinase 
inhibitor currently used as the standard of care in the treatment of chronic myeloid 
leukemia [5]. Resistance to targeted therapies can develop via a number of mechanisms 
and may be intrinsic or acquired. Intrinsic resistance can arise from a lack of expression 
of a drug target, a mutated drug target or via target-independent signaling mechanisms 
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[6]. For example, some patients are intrinsically resistant to HER2-targeted therapies 
because of the ability of HER2 to form heterodimers with other HER receptors, 
allowing differential intracellular signaling [7]. In contrast, acquired (also known as 
pleiotropic or evasive) resistance can develop in patients that were once responsive to 
treatment, and can arise from de novo mutations or from clonal selection of intrinsically 
resistant clones [8]. The development of acquired resistance renders targeted therapies 
ineffective and subsequent cancer recurrence often results in death from metastatic 
disease. This phenomenon is observed in the use of anti-estrogen, anti-androgen and 
Herceptin therapies for breast cancer treatment, and vemurafenib therapy in the 
treatment of late-stage melanoma [8]. 
The genomic, functional and spatiotemporal heterogeneity that is characteristic 
of many solid tumors plays a key role in the development of resistance to targeted 
therapies (Figure 1) [9, 10]. Mechanisms of acquired resistance to molecular-targeted 
therapies have been extensively reviewed elsewhere [11, 12]. The intratumoral 
heterogeneity of tumors provides a template for the clonal selection and expansion of 
target-negative tumor cells [13] and is a known mechanism of acquired resistance to 
targeted therapies [14, 15]. Within a cancer subtype, individual tumors are comprised of 
a mixture of both target-positive and target-negative tumor cells [16]. The 
administration of a targeted therapy inevitably places a selection pressure on a 
genetically and functionally heterogeneous population of tumor cells, resulting in the 
selection of tumor cells that are no longer responsive to the targeted therapy [17]. With 
both time and the continuation of therapy, the negative tumor cell population is able to 
expand such that the tumor becomes predominately target-negative, at which point the 
patient no longer shows a response to the original targeted therapy [18]. In this way, the 
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intratumoral heterogeneity of cancer can reduce the potential efficacy of targeted 
therapies and thus contribute to cancer recurrence and metastasis [19]. 
Figure 1: Schematic representation of inter-tumoral and intra-tumoral (biomarker) 
heterogeneity, including receptor and signaling heterogeneity. 
 
The intratumoral heterogeneity characteristic of many tumor types suggests that a 
multiple-targeting strategy directed against a broader range of tumor cell (and tumor-
associated immune cell) subtypes may be of benefit [20]. There is some evidence 
supporting the efficacy of targeting two or more different tumor cell receptors and/or 
populations using selective targeted therapies in order to improve the anti-tumor effect 
of mono-targeted therapies. Preclinical data supports the notion of combining two 
HER2-targeted therapies to achieve a synergistic anti-tumor effect in HER2-positive 
breast cancers [21]. The administration of antibodies trastuzumab and certuxumab, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
targeting HER2 and the human epidermal growth factor receptor (EGFR), respectively, 
in combination therapy has entered a phase I/II clinical trial in order to improve 
treatment efficacy of advanced pancreatic cancer [22]. The siRNA-mediated 
simultaneous knockdown of both HER2 and protein tyrosine kinase 6 in preclinical 
models of HER2-positive breast cancer reduced migration, invasion and cell 
proliferation of trastuzumab-resistant breast cancer cells in vitro, and a reduction of 
tumor growth in vivo, demonstrating a potential approach for treating breast cancer [23]. 
Additionally, recent evidence has shown that other cell types that support tumor cell 
growth and play key roles in facilitating metastasis, including endothelial cells, 
fibroblasts and immune cells, may too be potential targets for novel multi-targeted 
therapies [24]. For example, the superior efficacy of independently targeting both tumor 
and immune cells in various cancer types has been demonstrated previously [25, 26]. 
Several receptor-targeted molecular therapies have been developed to treat 
cancer, including a range of monoclonal antibodies and antibody fragments that derive 
an anti-tumor effect through binding to cell surface receptors in order to inhibit tumor 
cell proliferation [27]. Another tumor cell targeting approach involves the use of 
monoclonal antibodies, proteins or other ligands to facilitate target cell uptake of 
specific molecules to achieve an anti-tumor cell effect. For example, if the binding of a 
ligand to its target receptor results in the receptor-mediated endocytosis of the ligand-
receptor complex, the targeting ligand – which may be a currently-used targeted 
molecular therapy – can be used for the intracellular delivery of covalently-attached 
cytotoxins or other molecules to tumor cells that express the ligand receptor [28, 29]. 
This tumor targeting approach may help to circumvent intrinsic resistance driven by 
alternative signaling mechanisms [30]. While the plasma half-life of most targeted 
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molecular therapies tends to be relatively short, association of these molecules with 
larger nanostructures, such as lipid-based nanoparticles or liposomes, can significantly 
extend the plasma circulation time of the targeted therapy and increase the therapeutic 
payload delivered to the tumor site [31]. Such receptor-targeted nano-particulate 
therapies may incorporate currently-used targeting molecules, such as antibodies, onto 
the surface of the nanoparticle so that they can be used as targeting ligands to direct the 
nanoparticles to receptor-positive tumor cells and facilitate cellular uptake of the 
nanoparticle, achieving intracellular delivery of the nanoparticle cargo for anti-tumor 
effect. This is of particular importance for the targeted delivery of therapeutic 
macromolecules, including DNA, RNA and proteins, which otherwise would not be 
able to enter cells. 
 
Liposomes for Tumor Targeting and Drug Delivery 
Liposomes have emerged as a useful delivery system for the transport of drugs and 
other molecules to solid tumors [32]. Liposomes are spherical lipid-based vesicles, 
typically 100-200 nanometers in diameter, comprised of associating phospholipids that 
form a lipid bilayer surrounding an aqueous core (Figure 2) [33]. This unique structure 
allows for the encapsulation of hydrophobic or hydrophilic drugs, or other small 
molecules, in the lipid bilayer or aqueous core, respectively [34]. The circulation time 
of liposome particles is largely dependent on their lipid composition, size, surface 
charge, morphology and other physicochemical characteristics. The dominant 
mechanism by which liposomes are typically cleared from the bloodstream is based on 
interactions with the phagocytic cells the mononuclear phagocyte system (MPS). The 
inclusion of hydrophilic polymers, most commonly polyethylene glycol (PEG), at the 
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outer surface of the liposomes, can increase the in vivo circulation time by reducing 
recognition and clearance by the MPS [35]. For this reason, PEGylated liposomes have 
long been considered a clinically useful nanoparticle for drug delivery applications. 
However, despite the general trend of improved circulation time of PEGylated 
liposomes, researchers have found that the circulation time is dependent not only on the 
liposome type, but also on the number of injections administered [36]. The Accelerated 
Blood Clearance (ABC) phenomenon describes how the first dose of a PEGylated 
nanoparticle may affect the pharmacokinetic properties of subsequent doses; 
specifically, an increased clearance rate of PEGylated nanoparticles from the blood was 
observed with second and subsequent intravenous injections of the formulation [37, 38]. 
In this context, reduced circulation time correlates with increased liver and spleen 
accumulation [38]. While the exact mechanism of the ABC phenomenon remains 
unknown, a key identified mechanism is the production of anti-PEG IgM following the 
first injection, which selectively binds to the surface of subsequently injected 
PEGylated particles and acts to accelerate clearance by substantial complement 
activation [39]. The ABC phenomenon has been described for PEGylated liposomes, 
polymeric nanoparticles and PEGylated solid lipid nanoparticles delivered 
intravenously [40]. In other reports, an initial subcutaneous injection of a PEGylated 
nanoparticle has similarly been shown to reduce the circulation time of subsequent 
intravenous injections of the nanoparticle [41]. To assess whether the FDA-approved 
PEGylated liposomal doxorubicin formulation, Doxil®, induces the ABC phenomenon, 
studies in rodents, dogs and non-human primates have demonstrated a dose dependent 
loss of long circulation of Doxil® upon multiple intravenous injections [42]. 
Importantly, amongst other factors, the occurrence of the ABC effect is dependent on 
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the lipid dose administered (relatively high in the case of Doxil®) and duration of the 
administration interval (being much longer, i.e. 3-4 weeks, in case of Doxil®), making 
clinical Doxil® treatment insensitive to the ABC phenomenon [38, 43]. In a recent case 
study, Doxil® was found to activate the complement system in animals and humans, 
leading to a hypersensitivity reaction known as Complement Activation Related 
Pseudoallergy (CARPA), which would indeed impact upon the pharmacokinetics and 
pharmacodynamic properties of the drug [44]. Such research demonstrates that the ABC 
phenomenon is an important factor to consider in the design and development of 
PEGylated liposomes and other nanopharmaceuticals for repeat dosing therapeutic 
applications. 
 
 
Figure 2: General structures of non-ligand (passively targeted), and single-ligand and 
dual-ligand (actively-targeted) drug-loaded liposomes. 
 
Liposome-based drug formulations can offer several distinct advantages over free drug 
in addition to an increased in vivo circulation time, including improved stability and 
solubilization of encapsulated drug, reduction in systemic toxicity of the drug and 
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increased drug delivery to the tumor site [45]. The superior activity of drug-loaded 
liposomes relies on a multi-step process involving both passive and active targeting 
mechanisms. Passive targeting is primarily mediated by the enhanced permeability and 
retention (EPR) effect, defined as the extravasation and retention of particles less than 
380-780 nm in size into the tumor interstitial space due to highly porous tumor 
vasculature and poor lymphatic drainage from the tumor site [46, 47]. The encapsulated 
drug can be released from liposomes in the tumor interstitium and then taken up by the 
tumor cells, or the liposomes containing the drug are internalized by the tumor cells or 
other tumor-associated cells [48]. Therefore, in theory, passive targeting enables 
targeting to tumors via the EPR effect. In addition, liposome formulations reduce 
exposure of normal tissues to the drug as liposomes cannot pass through intact 
continuous endothelium, and so do not localize there (except for liver and spleen which 
have different anatomy of vasculature), minimizing associated off-target effects while 
simultaneously providing a mechanism for enhanced accumulation in the tumor site. 
The variability and limitations surrounding drug targeting via the EPR effect will be 
discussed in detail below. 
In addition to their versatile drug encapsulation capabilities, liposomes permit 
the active targeting of specific cell types via the conjugation of ligands, such as 
monoclonal antibodies, antibody fragments, proteins, peptides, carbohydrates, 
glycoproteins, aptamers and small molecules, to the liposome surface for drug delivery 
to cells expressing the target surface receptor(s) of interest [49]. Active targeting using 
liposomes is achieved via conjugation of one or more ligands to the liposome surface to 
form liposomes that bind to a target receptor(s) expressed on the tumor cell surface. 
Following liposome extravasation into the tumor interstitial space, subsequent ligand-
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directed surface binding and internalization (usually via receptor-mediated endocytosis) 
promotes liposome and drug entry into specific cell types. As actively-targeted 
liposome formulations combine both passive and active drug delivery mechanisms, 
ligand-directed liposomes should show superior drug delivery compared to non-ligand 
liposomes, depending on tumor type [50]. 
Currently, all clinically-approved liposome drug formulations are non-ligand 
directed, with efficacies relying solely on passive targeting to achieve tumor 
accumulation. Despite extensive research into nanomedicine-based therapeutics, and the 
preclinical development of dozens of liposome drug formulations spanning several 
decades, less than a dozen liposomal drug formulations have been approved by the FDA 
for clinical use to date [51, 52]. Of these FDA-approved liposomes, only several distinct 
formulations have been approved for the treatment of cancer, including Kaposi’s 
sarcoma, acute lymphoblastic leukemia, pancreatic cancer, ovarian cancer, multiple 
myeloma and metastatic breast cancer (Table 1). Evidently, there is a bottleneck in the 
translation of liposomes from preclinical development through to clinical utility, with 
many preclinical formulations never proceeding to clinical trials, and only a small 
percentage of those that do eventually making it onto the market. This bottleneck is 
even more profound for the development of ligand-directed liposomes, where there are 
currently no clinically-approved formulations available [53]. 
Active targeting strategies using ligand-directed liposomes have been explored 
extensively in the preclinical setting, showing improved efficacy over non-ligand 
liposomes in in vitro and in vivo models. For example, in vitro testing of doxorubicin-
loaded liposomes (analogous to Doxil®) that were surface-functionalized with an anti-
HER2 monoclonal antibody fragment demonstrated effective binding to breast cancer 
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cells expressing HER2 and a 700-fold increase in drug uptake compared to non-ligand 
directed liposomes in vivo [54]. MM-302, a HER2-targeted liposomal formulation of 
doxorubicin, showed efficacy in xenograft models of breast cancer and proceeded 
through to clinical trials [55]. A phase II/III clinical trial comparing trastuzumab therapy 
in combination with either MM-302 or chemotherapy of physician’s choice was 
recently terminated as the trastuzumab/MM-302 treatment did not show improved 
efficacy over the current standard of care for HER2-positive breast cancer [56]. This 
may be due to the current lack of understanding around how actively-targeted liposomes 
behave in immune-competent animals (i.e. humans). The development of actively-
targeted liposomes to improve the efficacy of their passively-targeted predecessors has 
been explored preclinically, with many formulations progressing through clinical trials 
(Table 1). However, as indicated above there are currently no clinically-approved 
ligand-directed liposome formulations [53]. Given the long history of ligand-directed 
liposomes and the significant investment of research into this area, it is important to 
explore the reasons why there has been limited translation of actively-targeted 
liposomes in the field of cancer therapy. Following an overview of previous research in 
the field, we will highlight and discuss some of the likely reasons for this bottleneck in 
clinical progression. 
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Table 1: Non-ligand, single-ligand and dual-ligand liposomes in clinical use, clinical 
trial and preclinical development for cancer treatment. 
Type Name Cargo Targeting 
ligand(s) 
Indication Status Reference 
Non-
ligan
d 
Doxil®/Caelyx
™ (Janssen) 
Doxorubicin - Kaposi’s 
sarcoma 
Ovarian 
cancer 
Multiple 
myeloma 
Metastatic 
breast 
cancer 
FDA 
approved 
(1995) 
FDA 
approved 
(2005) 
FDA 
approved 
(2008) 
FDA 
approved 
(2012) 
[57] 
[58] 
[59] 
[60] 
DaunoXome® 
(Galen) 
Daunorubicin - Kaposi’s 
sarcoma 
FDA 
approved 
(1996) 
[61] 
Myocet® (Elan 
Pharmaceutical
s) 
Doxorubicin - Metastatic 
breast 
cancer 
EMA 
approved 
(2000) 
[62] 
Marqibo® 
(Onco TCS) 
Vincristine - Acute 
lymphoblast
ic leukemia 
FDA 
approved 
(2012) 
[63] 
Onivyde® 
(Merrimack) 
Irinotecan - Metastatic 
pancreatic 
cancer 
FDA 
approved 
(2015) 
[64] 
Vyxeos™ 
(Jazz 
Pharmaceutical
s) 
Daunorubicin, 
cytarabine 
- Acute 
myeloid 
leukemia 
FDA 
approved 
(2017) 
NCT025331
15 
LEP-ETU Paclitaxel - Lung 
squamous 
cell 
carcinoma 
Phase IV 
clinical 
trials 
NCT029962
14 
EndoTAG-1 Paclitaxel - Breast 
cancer 
Pancreatic 
cancer 
Phase III 
clinical 
trials 
Phase III 
clinical 
trials 
NCT030021
03 
NCT031264
35 
Liposomal 
cytarabine 
Cytarabine - Breast 
cancer 
Phase III 
clinical 
trials 
NCT016458
39 
ThermoDox Doxorubicin - Hepatocellul
ar 
carcinoma 
Phase III 
clinical 
trials 
NCT021126
56 
NCT028504
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Breast 
cancer 
Phase II 
clinical 
trials 
19 
Liposomal 
Grb-2 
Grb2 
oligodeoxynucleot
ide 
- Acute 
myeloid 
leukemia 
Phase II 
clinical 
trials 
NCT027818
83 
Vincristine 
sulfate 
liposome  
Vincristine - Acute 
myeloid 
leukemia 
Phase II 
clinical 
trials 
NCT023374
78 
Mitoxantrone 
hydrochloride 
liposome 
Mitoxantrone - Metastatic 
breast 
cancer  
Phase II 
clinical 
trials 
NCT025963
73 
SPI-077 Cisplatin - Advanced 
solid tumors 
Phase I/II 
clinical 
trials 
NCT018614
96 
LiPlaCis Cisplatin - Advanced 
solid tumors 
Phase I/II 
clinical 
trials 
NCT018614
96 
Liposomal 
dexamethasone 
Dexamethasone - Multiple 
myeloma 
Phase I/II 
clinical 
trials 
NCT030333
16 
MM-398 Irinotecan - Recurrent 
solid tumors 
Phase I 
clinical 
trials 
NCT020133
36 
Singl
e-
ligan
d 
Anti-EGFR 
immunoliposo
me 
Doxorubicin Cetuximab 
Fab 
fragment 
Breast 
cancer 
Phase II 
clinical 
trials 
NCT028337
66 
Dual-
ligan
d 
Anti-
CD19/CD20 
liposomes 
Doxorubicin Anti-CD19 
and anti-
CD20 
monoclona
l antibodies 
B cell 
lymphoma 
Preclinical 
developme
nt 
[65] 
T7/TAT-LP-
PTX 
Paclitaxel Ligand 
peptide 
(HAIYPR
H), 
cationic 
cell 
penetrating 
peptide 
(TAT) 
Lung cancer Preclinical 
developme
nt 
[66] 
P-selectin/avβ3 
integrin 
liposome 
Fluorescent 
marker 
Peptides 
targeting P-
selectin 
and avβ3 
integrin 
Metastatic 
breast 
cancer 
Preclinical 
developme
nt 
[20] 
Integrin avβ3 
peptide/[D]-
H6L9 
Paclitaxel Integrin 
avβ3 
peptide, 
Colon 
cancer 
Preclinical 
developme
nt 
[67] 
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liposome [D]-H6L9 
peptide 
RGD/TF-LP Paclitaxel Cyclic 
arginine-
glycine-
aspartic 
acid (RGD) 
and 
transferrin 
(TF) 
Brain 
glioma 
Preclinical 
developme
nt 
[68] 
EMA, European Medicines Agency; FDA, Food and Drug Administration. The ClinicalTrials.gov 
identifier is listed as the reference for liposomes in clinical trials. 
  
Dual-Ligand Liposomes for Dual-Targeting Approaches in Cancer 
Liposomes have been used for tumor targeting for several decades, and while no single-
ligand or dual-ligand liposomes have yet been clinically adopted, such targeted 
liposome formulations have been reported extensively in the literature. The utilization 
of a dual-targeted approach has a range of reported purposes; most commonly, for 
overcoming intratumoral heterogeneity by targeting multiple tumor cell subtypes and 
targeting tumor-associated cells; for targeting tumor vasculature as a means to halt 
tumor growth; and for facilitating nanoparticle delivery across biological barriers, such 
as the blood-brain barrier, for drug delivery to the brain.  
 
Dual-Ligand Liposomes for Targeting Two Tumor Cell Receptors 
Given the demonstrated performance of non-ligand liposomes in drug delivery and the 
large number of studies describing the design of ligand-bearing liposomes to target 
tumor-associated receptors, the development of liposomes that can target more than one 
tumor cell subtype in a heterogeneous tumor may help to overcome therapeutic 
limitations of current therapies (Figure 3). Previous in vitro and in vivo studies have 
demonstrated that ligand-directed liposomes targeting two different cell surface 
receptors can increase the amount of total liposome binding to the cancer cells within a 
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tumor, as the liposome is able to bind to any target cell expressing either receptor, 
which increases the breadth of targeting. 
Figure 3: Targeting multiple tumor cell subtypes using dual-ligand directed liposomes 
may help overcome therapeutic limitations caused by inter-tumoral heterogeneity of 
cancer. Liposomes bearing two disparate ligands enable liposome uptake via receptor-
mediated endocytosis by tumor cells bearing either (or both) target receptors, thus 
increasing the range of tumor cell targeting. Single-ligand liposomes only enable 
targeting of the tumor cells bearing the target receptor. Given the intratumoral 
heterogeneity of cancer, some tumor cells will not be targeted, and instead that 
population may be able to expand. Ligand-directed liposomes may also be designed to 
target stromal cells for an intended anti-tumor effect. 
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Several preclinical studies have successfully modified liposomes with two 
surface-bound moieties to create ligand-directed, drug-loaded liposomes that show 
specific binding to receptor-bearing tumor cells, and a resultant higher tumor cell uptake 
and kill than non-targeted or single-ligand liposomes [69]. For example, the cellular 
uptake and cytotoxicity of dual-ligand liposomes targeting lymphoma biomarkers CD19 
and CD20, or an equal combination of the two single-ligand liposomes at equal 
antibody amounts, was greater than for either single-ligand liposome alone [70]. 
Similarly, a pH-sensitive doxorubicin-loaded liposome formulated to promote 
intracellular drug release was surface-functionalized with folic acid and AS1411 
aptamer (targeting the folate receptor and nucleolin, respectively) and showed increased 
cancer-targeting and efficacy relative to single-ligand and non-ligand liposomes [71]. 
Dual-ligand liposomes showed enhanced cellular uptake, higher intracellular delivery of 
doxorubicin and greater apoptosis in human breast and pancreatic cancer cell lines than 
single-ligand liposomes, and had no adverse doxorubicin-related effects on a non-
cancerous human cell line. Using a murine model of human B-cell lymphoma, drug-
loaded liposomes functionalized with antibodies targeting CD19 or CD20 showed 
improved outcome compared to non-ligand liposomes, with a trend of increased 
therapeutic efficacy for a combination of the two compared to each alone [70]. 
Liposomes containing paclitaxel and bearing both a cell ligand peptide and cell 
penetrating peptide to target lung cancer showed greater liposome internalization in 
lung cancer cells, greater accumulation of paclitaxel in tumor spheroids, and 
significantly greater inhibition of tumor growth in a mouse model of lung cancer than 
single-ligand and non-ligand liposomes [66]. Dual-ligand paclitaxel-loaded liposomes 
containing the integrin avβ3 peptide and an anti-microbial peptide showed increased 
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cellular toxicity and improved tumor growth inhibition in a colon carcinoma mouse 
model relative to single-targeted liposomes [67]. This improved delivery effect of dual-
ligand over single-ligand targeting was also demonstrated using a nanostructured lipid 
carrier containing plasmid DNA that was surface-functionalized with both transferrin 
and hyaluronic acid, which showed increased transfection efficiency than single-ligand 
or non-ligand carriers in a mouse model of lung cancer [72]. While the ligand density 
and stoichiometry were not quantified in any examples, we hypothesize that ligand-
directed liposomes targeting two different cell surface receptors can increase the total 
amount of liposome binding to the tumor cell surface within a heterogeneous tumor, as 
the liposome is able to bind to any target cell expressing either receptor (Figure 3). This 
is likely to increase the breadth of cellular targeting beyond a single receptor/cell type, 
subsequently enhancing drug uptake, dose and hence the anti-tumor effect [65]. 
Furthermore, dual-ligand liposomes could act to unify the pharmacokinetic and 
biodistribution properties of different ligand-functionalized liposomes for precise 
delivery to target cells as compared to using two individual ligand-functionalized 
liposomes with disparate targeting moieties and pharmacological profiles. 
 
Dual-Ligand Liposomes for Targeting the Tumor and its Microenvironment 
The tumor microenvironment which consists of fibroblasts, immune cells, vasculature, 
and extracellular matrix (ECM) components such as collagen and fibrin, has 
increasingly been found to play a key role in tumor progression, metastasis and 
response to therapy. Treatment strategies that target aspects of the tumor 
microenvironment such as anti-angiogenic and immunostimulatory therapies show 
promising preclinical and clinical results; however, factors such as lack of drug 
penetration into the tumor, non-specific drug delivery, rapid clearance from serum, or 
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toxic side effects contribute to the failure of many conventional therapies to completely 
eliminate the tumor. Dual-ligand liposomes offer a potential solution to some of the 
aforementioned problems, as many recent studies have shown encouraging results using 
nanomedicines to target the tumor vasculature, the ECM and cancer associated immune 
cells [73]. For example, Doolittle et al. described the creation of dual-ligand liposomes 
targeting two different angiogenesis-specific receptors overexpressed at different stages 
of metastatic disease. Given tumors display a dynamic, heterogeneous 
microenvironment, that undergoes spatiotemporal changes in the expression of cell-
surface biomarkers during disease progression, the authors reasoned that targeting P-
selectin and αvβ3 integrin would target the liposome towards blood vessels associated 
with metastases at different stages of disease progression. Here, a metastatic site 
transitions, after initial adhesion of circulating tumor cells onto endothelium, from P-
selectin-dependent cell rolling on the endothelium to firm attachment that is αvβ3 
integrin-mediated [74]. In a resectable mouse model of metastatic triple-negative breast 
cancer their dual-ligand strategy achieved complementary targeting of different tumor 
sites that was missed using two independent single-ligand liposomes. This was 
attributed to poor co-localisation of both single-ligand liposomes at metastatic sites at 
the same point in time [20]. This approach was similarly demonstrated by Kluza et al in 
the context of magnetic resonance imaging of angiogenesis [75].  
 Spatiotemporal changes in the expression of cell-surface molecular markers is 
also observed in cancer stem cells (CSCs), a small population of cells within a tumor 
with the ability to undergo both self-renewal and differentiation. CSCs are now 
recognized for their role in driving the initiation, invasion, metastasis, resistance and 
recurrence of a tumor and the development of targeted nanotherapies that disrupt the 
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maintenance and survival of CSCs are the subject of intense research [76]. For example, 
a multi-functional nanoparticle conjugated to a ligand targeting a specific CSC marker; 
and a chemosensitizer (such as an ABC transporter inhibitor) to overcome drug 
resistance has been proposed [76]. Altogether these studies further support the potential 
advantage of a multiple receptor targeting strategy using dual-ligand liposomes to better 
target the spatiotemporal changes in receptor expression that occur during metastatic 
disease progression. Additional examples of potential target combinations for the design 
of dual-ligand liposomes are listed in Table 2. 
 
Table 2: Potential target receptors for the design of dual-ligand liposomes with the 
ability to concomitantly target the tumor and its dynamic microenvironment. 
Cancer type Biomarker 1 Cell population targeted  Biomarker 2 Cell population targeted  
Breast  HER2 
ER  
EGFR  
Tumor cells [77] 
Tumor cells [78] 
Tumor cells [79] 
ALDH-1  
CTLA-4  
uPAR  
 
 
CSC [80] 
CSC [81] 
Activated fibroblasts  and 
tumor-associated 
macrophages [82], invasive 
tumor cells [83] and CSC 
[84] 
Pancreatic EGFR  
uPAR 
CD109  
Tumor cells [85] 
Tumor cells [86] 
Tumor cells [87] 
CD133 
CD44  
CD24 
CSC [88] 
CSC [89] 
CSC [90] 
Melanoma  AXL receptor 
tyrosine 
kinase  
Tumor cells [91] CD20
+  
 
 
VEGFR 
Tumor-associated B cells 
(in cutaneous melanoma) 
[92] 
Endothelial cells [93] 
Prostate PSMA Tumor cells and new 
blood vessels [94] 
CD44/CD133 
 
CSC [95] 
 
Colorectal uPAR 
 
Tumor cells and tumor-
infiltrating macrophages 
[96] 
VEGFR 
EpCAM 
Endothelial cells [97] 
CSC [98] 
HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; EGFR, epidermal growth factor 
receptor; ALDH-1, aldehyde dehydrogenase 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; 
uPAR, urokinase plasminogen activator receptor; CSC, cancer stem cell; CD, cluster of differentiation; 
VEGFR, vascular endothelial growth factor receptor; PSMA, prostate-specific membrane antigen; 
EpCAM, epithelial cell adhesion molecule 
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Dual-Ligand Liposomes for Overcoming Biological Barriers  
In the context of glioma treatment, ligand-directed liposomal drug formulations may 
enhance drug transport across the blood-brain barrier (BBB) for drug delivery to the 
brain [99]. Dual-ligand liposomes containing daunorubicin and surface-functionalized 
with both transferrin and p-aminophenyl-α-D-manno-pyranoside showed increased 
transport across the BBB, increased cellular uptake and increased survival compared to 
treatment with free daunorubicin in a rat model of brain glioma [100]. Another study 
using doxorubicin-loaded liposomes surface-functionalized with transferrin and one of 
two different cell-penetrating peptides showed improved delivery of doxorubicin across 
the brain endothelial barrier (BEB) compared to single-ligand and non-ligand liposomes 
in vitro, and efficient translocation across the BEB in an in vitro brain tumor model 
[101]. Similarly, docetaxel-loaded nanoparticles that were surface-functionalized with 
IL-13 and RGD peptide to target both tumor cells and neovasculature showed greater 
uptake in a glioma cell line than single-ligand and non-ligand nanoparticles, and the 
dual-ligand nanoparticle induced higher apoptosis of cells in the glioma site in vivo, 
indicating an improvement in cell uptake and the anti-tumor effect by dual-targeting 
[102]. This was further supported by experiments using dual-ligand liposomes bearing 
both an aptamer and a peptide moiety to target glioma and the BBB in an in vitro 
glioma model designed to recapitulate the tumor microenvironment [103]. Collectively, 
the aforementioned studies demonstrate the potential utility of dual-ligand directed 
liposomal drug formulations for cancer therapy, with an increased degree of liposome 
uptake acting to improve the anti-tumor effect. 
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Challenges and Outstanding Questions 
Despite convincing preclinical research in the field of ligand-directed liposomes for the 
treatment of solid tumors and other diseases, there has been limited progression of 
targeted liposome formulations towards clinical application [104]. There are several 
important factors that may be responsible for this lack of clinical development of 
targeted liposomes past the preclinical stage. 
 
Large-Scale Production of Ligand-Directed Liposomes 
Most – if not all – of the current clinically approved nanotherapies are arguably quite 
simplistic in their composition and structure, a characteristic which is well regarded by 
the processes of large-scale manufacture – for example, Doxil. However, laboratory-
based preparation and testing of ligand-directed liposomes is usually performed on a 
small scale, often in milliliter quantities. Volumes produced at this small scale are 
sufficient for in vitro and in vivo testing, but upscaling of ligand-directed liposome 
production – as required for clinical use – can be challenging, since currently-used lab-
based liposome production methods are generally not amenable to scale up beyond the 
milliliter scale. For example, the formation of liposome thin films via use of rotary 
evaporation is limited by the size of the flask used to create the film, and flask 
overloading may increase liposome polydispersity and alter other physicochemical 
characteristics of the resultant sample [105]. The extrusion of liposomes through 
membranes as required to achieve a desired size distribution is another labor-intensive 
step in the production process, as preparations need to be passed repeatedly across a 
membrane and usually on a 1-20 milliliter scale. In the laboratory setting, preparation of 
multiple separate batches of ligand-directed liposomes can be used to overcome these 
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issues. However, the current lack of established methods to quantify the ligand density 
on the surface of liposomes means that it is difficult to account for batch-to-batch 
variability of a ligand-directed liposome formulation, and even more so for dual-ligand 
or multi-ligand liposomes. Without robust methods to enable detection of ligand 
conjugation and quantification of surface ligands, variation between batches may lead to 
deviations in the physicochemical characteristics of the preparation, which would 
ultimately influence stability, in vivo circulation time, clearance properties, tumor 
uptake, therapeutic efficacy and toxicity of a targeted liposome formulation [106]. 
 
Characterization of Ligand-Directed Liposomes 
Various methods for liposome characterization are well documented. Commonly 
measured characteristics include: liposome size and polydispersity by dynamic and 
static light scattering; surface charge by measuring zeta potential; degree of drug 
encapsulation by spectrophotometry or high performance liquid chromatography; and 
morphology and physical state by cryo-transmission electron microscopy and atomic-
force microscopy [107]. The development of methods to characterize more complex 
liposomes, particularly ligand-directed liposomes, are lacking and this is a significant 
barrier to the feasible and practical development of actively targeted liposomes for 
clinical utility. Controlling for batch-to-batch variability is difficult without effective 
methods for characterization, and the inability to control or correct for variability in 
ligand attachment to liposomes will become an issue in the regulatory processes 
required for clinical translation of a novel formulation. Notably, adequate methods for 
the confirmation and quantification of ligand attachment to liposomes have not been 
reported [108]. The direct measurement of small amounts of protein in a targeted 
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liposome formulation using biochemical assays is often problematic due to 
phospholipid interference, and if successful only provides a quantification of the total 
protein in a liposome sample, rather than a quantification of the average number of 
protein ligands bound to each liposome. Characterization of ligand-directed liposomes 
has been performed using indirect assays, such as flow cytometric methods that detect 
the insertion of fluorescently-labelled micelles (to which protein ligands are bound) into 
liposomes to confirm that ligand incorporation into the liposome has occurred, but these 
methods are only semi-quantitative at best [109]. Understandably, this poses a larger 
challenge for dual-ligand and multi-ligand liposomes, where the determination of 
stoichiometry of ligand attachment becomes an important step in the characterization 
process. Theoretical values of ligand conjugation and ligand ratios have been reported 
but this has not been demonstrated empirically for most liposome formulations, as the 
methods used to generate such data are technically challenging. Our group has recently 
developed a novel single-molecule fluorescence imaging technique that is able to 
quantify the density and stoichiometry of proteins attached to the surface of liposomes 
with high sensitivity. By removing ensemble averaging, single-molecule approaches 
allow the direct visualization of liposome population distributions and the precise 
characterization of sub-populations, and the ability to detect single-molecule changes 
therein (Belfiore et al., under review at Journal of Controlled Release). 
An important consideration in the characterization of ligand-directed liposomes 
concerns questions beyond the in vitro setting and in the context of the in vivo 
biological milieu. Specifically, the question of what happens to liposome integrity, 
ligand attachment, ligand function, and therefore the biophysical properties of a 
liposome formulation after intravenous administration, including in vivo circulation 
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time and clearance properties of the liposomes. The well-documented propensity of 
biological molecules, especially proteins, present in the bloodstream to associate non-
specifically with the surface of liposomes in vivo, and the subsequent formation of a 
protein ‘corona’ around the liposome may affect numerous biophysical properties of a 
liposome formulation. In the case of ligand-functionalized liposomes, the physical 
presence of a protein shield around the surface of the liposome, including association of 
plasma proteins with liposome ligands, may act to inhibit binding of the liposome 
targeting ligand with its target receptor, therefore reducing or masking the targeting 
ability of the liposome, which would affect the targeting success in vivo [51]. Such 
potential changes to the liposome are usually unaccounted for in the in vitro setting but 
could indeed affect the anticipated biodistribution, pharmacokinetics and efficacy 
profiles of a liposome formulation [110]. Therefore, it is important to consider these 
effects in biological testing systems, noting that attempting to recapitulate such effects 
in vitro comes with inherent limitations. 
Another aspect for consideration is the potential negative effects that ligand-
directed liposomes may have on healthy tissues. In order to minimize off-target effects, 
target receptors are usually chosen based on their very high expression on tumor cells 
relative to healthy cells [111]. To demonstrate this point, Park et al. reported that a 
receptor density of 105 HER2 molecules per cell was required for increased therapeutic 
effect of HER2-targeted liposomal doxorubicin over non-targeted liposomal 
doxorubicin in a metastatic breast cancer model [112]. Similarly, the differential 
expression of estrogen and progesterone receptors in hormone receptor-positive breast 
cancer, compared to healthy tissue, are useful indicators of response to therapy [113]. 
Indeed, many of the current FDA-approved molecular targeted therapies for cancer, 
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including trastuzumab, lapatinib and pertuzumab in the case of breast cancer, involve 
targeting receptors with very high prevalence on tumor cells in order to attain a degree 
of targeting sufficient to achieve the therapeutic response. 
While there are now comprehensive libraries that catalogue a variety of new 
potential ligands for nanotherapeutic applications [114], the basic principle of ligand-
mediated targeting remains constant and is subject to two critical criteria; the 
accessibility of the target receptor for ligand binding, and whether receptor binding 
leads to cellular internalization. Targeting ligands need to be highly selective, but also 
relatively safe – and in the case of utilizing a ligand to direct a nanoparticle to a target 
cell, rather than using the ligand itself to exert an anti-tumor effect, the ligand need not 
be toxic. However, this can be difficult to assess, as even if the free ligand is studied for 
toxicity, the toxicity profile may be very different after coupling to the surface of 
liposomes. Commonly-used ligands, such as folate and transferrin, have been relatively 
well-characterized using in vitro and in in vivo models. Folate-targeted nanoparticles 
functionalized with folate ligands have shown low systemic toxicity in a mouse model 
of epidermoid carcinoma [115]. Liposomes surface-coated with hyaluronan have shown 
no measured cytokine induction after intravenous administration in mice, indicating no 
immune activation, despite the fact that administration of low-molecular weight 
hyaluronan itself has previously been shown to stimulate inflammatory responses [116]. 
Such studies highlight the importance of determining potential off-target effects of 
ligands for new ligand-directed liposome formulations. However, the effect of ligands 
on healthy cells and the immune system in the context of human diseases becomes 
difficult to ascertain without the development of models that enable accurate 
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determination of these systemic effects. This topic is discussed in the following 
sections. 
 
Models that Accurately Reflect Tumor Heterogeneity 
A diverse range of cancer cell lines derived from tumor biopsies have been established 
in the laboratory and retain many – but not all – of the genotypic and phenotypic 
properties of the original tumor cells, making them useful representative models for 
testing targeted therapies [117, 118] and to study mechanisms of therapeutic resistance 
[119]. However, despite their widespread use, cells grown in a two-dimensional (2D) 
monolayer do not adequately recapitulate several key elements of in vivo tumors, 
including three-dimensional (3D) tumor architecture, tumor cell interactions, tumor-
stroma interactions and the various proliferative and metabolic gradients that form when 
tumor cells exist as a 3D structure [120]. The absence of these features in cell 
monolayers is highlighted by differences in cell morphology and gene expression in 2D 
versus 3D cultures [121], and results in differences in responses to drug treatments. For 
example, the sensitivity of breast cancer cells to trastuzumab, pertuzumab and lapatinib 
changes depending on whether the cells are grown as 2D or 3D cultures [122], and the 
apparent differences in HER2 signaling observed between 2D and 3D cell culture 
models of breast cancer suggest that 3D models better recapitulate in vivo HER2 
signaling pathways [123]. Given their closer similarity to in vivo tumors, 3D models are 
generally considered more informative in the translation of in vitro results to in vivo and 
clinical settings [124]. Multicellular tumor cell spheroid models are a commonly used 
3D cell culture model in which cancer cells are grown as a spherical association 
resembling small tumors and micrometastases [125]. The ability of cancer cells to form 
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spheroids is strongly related to the expression of several cell-cell adhesion molecules 
[126] and can be facilitated by culturing cells in conditions that prevent adherence to the 
cell culture plate [127]. Changes in spheroid morphology and diameter in response to a 
drug treatment can be measured using manual or automated imaging techniques [128], 
and end-point biochemical assays allow for determination of cell viability [129]. 
Multicellular tumor cell spheroids may also be grown with additional extracellular 
matrix components (i.e. fibronectin and collagen), or support cell types that are 
associated with in vivo tumors, including tumor-associated fibroblasts which have been 
shown to influence tumor growth, invasiveness and overall disease progression [130], 
and therefore targeting of both the tumor microenvironment and tumor cells may 
produce synergistic anticancer effects. Such aspects of spheroids allow for the creation 
of a more clinically relevant model to study the interactions between distinct cell types 
in the tumor microenvironment and test the effects of novel targeted therapies while 
improving the translation of results from the in vitro to the in vivo setting [131]. 
While 3D and ex vivo models are considered more physiologically relevant than 
2D cell monolayers, most models still do not adequately capture the nature of tumor 
heterogeneity [132]. A single cancer cell line used in a spheroid model or even injected 
into an animal to create an in vivo model of disease fails to recapitulate the intratumoral 
heterogeneity that is observed in human tumors across many cancer types. As the cells 
are clonally similar, any treatment is expected to affect most if not all cells in that model 
in the same way. Therefore, using these models to develop and test novel therapies, 
especially targeted therapies that are designed to address intratumoral heterogeneity, is 
limited as they are not representative of the clinical situation and do not permit 
evaluation of therapeutic resistance. To address this, cell monolayers and spheroids can 
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be grown as co-culture models, where distinctly different cell lines are cultured together 
to recapitulate some aspects of tumor heterogeneity, but with limitations [133]. For 
example, these static models rely solely on passive drug diffusion to permeate the tumor 
cells or spheroids, and do not account for transport across the vascular endothelium. 
Further, they do not reproduce the complex vascular network, hypoxia, interstitial fluid 
pressure and fluid shear observed in the in vivo tumor microenvironment. In order to 
better understand the impact of tumor heterogeneity and the complexity of the tumor 
microenvironment, Kiani and colleagues have recently developed a microfluidic-based 
platform for monitoring drug delivery in a 3D environment recapitulating circulation, 
extravasation and delivery to the tumors across the interstitial space [134]. 
In addition to intratumoral heterogeneity, the interpatient heterogeneity observed 
in cancer warrants the development and utilization of patient-derived xenografts and 
patient-derived cell lines to more accurately assess patient responses to novel therapies, 
particularly in cases where resistance to currently used therapies is frequently observed 
[135]. Additionally, given the effect of the immune system in tumor growth and 
metastasis [136], there is a need for tumor models in immunocompetent animals in 
addition to the often-used immunocompromised models that eliminate potential effects 
of the immune system in the evaluation of new anticancer therapies [137]. The 
increasing use of such models lends itself to the improved assessment of targeted 
therapies in the context of cancer treatment. However, in vivo models should be chosen 
with care given the high level of variability observed between different animal models 
and disease states [138]. 
 
Accounting for the Enhanced Permeability and Retention Effect in the Preclinical 
Setting 
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The field of nanomedicine is founded on the central dogma of the enhanced 
permeability and retention (EPR) effect. Evidence for this phenomenon has been 
reviewed elsewhere [139] but the research to date collectively suggests that the EPR 
effect does appear to enable the passive accumulation of liposomes and nanoparticles to 
tumor sites. However, the EPR effect is reported to be highly variable between different 
tumor types and is not observed for all solid tumors [140, 141]. For solid tumors that are 
typically poorly vascularized, any significant accumulation of nanoparticles in the 
vicinity of the tumor via the EPR effect is unlikely [142]. In such cases, the application 
of nanoparticles in the treatment of some solid tumors may have greater potential for 
use in the adjuvant setting to target vascularized micrometastases, rather than (or in 
addition to) the primary tumor [143]. The nanoparticle targeting of hematological and 
lymphoid tumors, particularly for ligand-directed liposomes, has generally shown 
greater success in in vivo tumor models since tumor cells in circulation are more 
directly accessible to liposomes than large solid tumors immersed in complex 
microenvironments [144, 145]. 
The EPR effect is known to be highly variable between different animal models, 
different disease models and between animal models and the human patients [146], with 
the rate of animal model tumor growth and resultant angiogenesis much greater than the 
formation of a tumor in humans [147]. The EPR effect has been demonstrated in 
humans using CRLX101, a polymer-drug nanoparticle, which was shown to localize in 
patient tumors and not in adjacent tissues following administration [148]. In this 
experiment, the fluorescent nanoparticle signal observed was lower than that previously 
observed in mouse xenograft models. Given the observed differences in the EPR effect 
between animals and humans, the initially reported efficacies of many novel 
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nanotherapies are often much higher in preclinical models than later reported in humans 
due to the former having a more pronounced EPR effect [139], and this may partially 
explain why many nanotherapies that show promise in in vivo studies fail in clinical 
trials. The development of animal models that recapitulate the EPR effect at a level 
more analogous to the human condition would be of benefit in the initial evaluation of 
novel targeted nanotherapies. 
Whether via the EPR effect and/or via other mechanisms, it has been reported 
that only approximately 0.7% of the injected dose of nanoparticles administered 
intravenously accumulates in tumors in preclinical models [50]. However, it should be 
noted that the accumulation of nanoparticles in tumors via EPR is largely dependent on 
the in vivo circulation time of the nanoparticle formulation; for example, the tumor 
accumulation of Doxil® in humans has been reported as high as 10% of the injected 
dose, owing to the long circulation half-life of up to 45 hours [149]. While the 
percentage of injected dose accumulating in tumors may indeed be lower in humans due 
to noted differences in the EPR effect between species, previous studies have 
demonstrated a tangible effect of nanoparticle drug delivery to human tumors. For 
example, in a study of gastric cancer in humans, it was demonstrated that the degree of 
passive accumulation of nanoparticles in gastric tumors was sufficient to cause a down-
regulation of two target enzymes in the tumor tissue [148]. Although the EPR effect has 
only been directly demonstrated in animal models, this study indirectly supports the 
notion of accumulation of nanoparticles in human tumors for therapeutic effect, which 
may be due, wholly or in part, to the EPR effect. Further research is required to better 
understand the EPR effect and elucidate the differences in this phenomenon between 
animal and human tumors, and between different tumor types, in order to increase 
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translation of nanoparticle-based therapeutics into the clinic [150]. One way that this 
could be achieved is via imaging of radiolabeled liposomes to determine their fate in 
humans [151]. Single photon emission computed tomography (SPECT) and positron 
emission tomography (PET) have previously been used to quantify the in vivo 
distribution of nanoparticles, including accumulation of nanoparticles at the tumor site, 
in a non-invasive manner in locally advanced cancers of the head and neck, breast and 
cervix [152]. The use of nanoparticles in conjunction with such imaging techniques may 
also have theranostic applications, whereby both diagnostic and therapeutic agents are 
utilized in order to better guide and monitor treatment [153]. 
 
Emerging Trends and Future Directions 
The development of new methods and technologies to prepare and characterize ligand-
directed liposomes will enable a more comprehensive evaluation of ligand-directed – 
and importantly, dual-ligand – liposome formulations, to facilitate their clinical 
development. To meet the demands for large-scale preparation of liposomes as required 
for clinical use, microfluidic approaches have recently emerged as a way to produce 
large quantities of liposomes of a uniform size and consistent physicochemical 
properties, which may be a way forward for efficient and cost-effective liposome 
preparation [154]. With advances in technologies to prepare liposomes on a large scale 
and to create actively targeted liposomes using antibody engineering, the future for 
nanoparticle-based drug delivery strategies can permit multiple targeting of target cell 
types, including genetically distinct tumor cells, but also key cells of the tumor 
microenvironment that are known to play a role in supporting tumor growth and spread, 
including immune cells and cancer stem cells [155]. 
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The use of short chain antibody fragments as targeting ligands, as opposed to 
whole antibodies, is a promising strategy for creating actively targeted liposomes as the 
ligands can be engineered to optimize binding affinity and other physical properties for 
improved tumor cell targeting and uptake. As antibody fragments are smaller than 
whole antibodies, the immunogenicity may be lower and the in vivo circulation time of 
the resultant targeted liposomes more appropriate (i.e. more prolonged) for tumor 
targeting [156]. Recent technological developments have contributed to a shift away 
from conventional covalent coupling methods of attaching ligands to the surface of 
liposomes, and towards the specific engineering of antibodies and fragments for cellular 
targeting applications. Protocols to develop bispecific immunoliposome formulations 
using two different single-chain FV fragments on the liposome surface to target two 
different tumor cell populations have been reported and show a retention of binding 
activity of each ligand for its target receptor [109]. The creation of multivalent 
liposomal therapeutic antibody constructs to bind more than one antigen has been 
reported [157], as well as PEGylated hyper-branched polymers bearing two different 
targeting ligands [158]. The use of bispecific antibodies bound to the surface of 
liposomes potentially allows recognition of multiple antigens to achieve the same effect 
attained with conventional dual-ligand liposomes [159]. The successful development of 
a liposome with a single surface-attached bispecific antibody that can recognize and 
bind to both endoglin (CD105) and fibroblast activation protein demonstrates the 
feasibility of this approach in dual-targeting [160]. These approaches allow for more 
control in the stoichiometry of ligand targeting (i.e. always 1:1) compared to the 
traditional conjugation of two separate ligands, and for this reason may aid the 
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production and regulatory processes required for clinical use of actively targeted 
liposomes. 
The gradual movement away from simplistic monolayer and monoculture cell 
models and utilization of models that better recapitulate in vivo tumors, including 
computer simulated models [161], ex vivo multicellular tumor spheroid models, co-
culture models, biomimetic microfluidic tumor microenvironment models and patient-
derived xenografts, will allow for the inclusion of some aspects of tumoral 
heterogeneity and the contribution of the tumor microenvironment in the evaluation of 
novel nanotherapies. The use of other assessment approaches, such as comparative 
oncology in non-human patients with prostate or other spontaneous cancers that mimic 
the human disease are valuable models for assessing liposome efficacy [140]. These 
approaches are expected to help guide nanotherapy research in its early stages and 
provide a more accurate understanding of the expected efficacy should the formulation 
progress to clinical trials.  
To better guide the movement of novel liposomes into clinical trials, liposomes 
and other nanoparticles can be used in a theranostic setting, combining both diagnostic 
and therapeutic capabilities in a cancer context. Theranostic nanoparticles may bear a 
ligand for tumor targeting and a second ligand or other molecule for imaging in vivo. 
Radiolabeled liposomes have been previously detected in humans in vivo using positron 
imaging tomography imaging techniques [151]. Liposomes bearing a folate ligand and 
containing a photothermal agent offer both therapeutic and diagnostic functions, 
respectively, in the treatment and imaging of cancer in vivo [162]. Dual-ligand micelles 
with surface-bound trastuzumab and FLAG peptide showed co-localization of the 
antibody and peptide in SKBR-3 cells by confocal microscopy, while non-
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functionalized micelles showed no uptake, indicating tumor cell targeting and a 
receptor-dependent effect [163]. The theranostic potential of liposomes can also be 
utilized for companion diagnostics in the preselection of patients for clinical trials and 
use in the clinic, and is an area of developing research in the field [153]. 
 Finally, in addition to defining the precise liposome engineering conditions for 
optimal pharmacological profiles, there is a concomitant need to gain a thorough 
understanding of the aberrant biological processes driving disease in order to identify 
new molecular targets (and their ligands) for targeted drug delivery. Correlating the 
genotype of tumors to drug susceptibility will also help to establish guidelines for the 
use of targeted nanotherapies and to predict successful therapeutic outcomes. As 
reviewed in detail elsewhere [164, 165], many disease-specific ligands have been 
conjugated to liposomes in order to achieve site-specific drug delivery. Historically, 
these efforts have focused on the design of nano-delivery systems that utilize ligands 
(most commonly antibodies) to target breast, prostate and colorectal cancer; however, 
our ever increasing knowledge of the genetic or molecular alterations that underlie 
disease pathophysiology is providing novel targeting ligands. For example, thyroid-
stimulating hormone (TSH) has been attached to the surface of PEGylated liposomes 
with the aim of targeting the TSH receptor (thyrotropin receptor). TSH receptor 
expression is maintained in most thyroid pathologies, including benign and malignant 
tumors [166], but more importantly, is also present in the majority of less differentiated 
and more aggressive tumors [167], making it a novel opportunity for targeted delivery 
of chemotherapeutics. Such insights offer new avenues for improving therapeutic 
efficacy of nanotherapeutics and is critical for the success of next generation targeted 
therapeutic approaches. 
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Conclusions 
The first clinically-approved liposome, Doxil®, has been in use for over 20 years and is 
still used as an effective treatment for several cancer types. Despite this, the liposome 
field has not evolved into translating effective actively-targeted analogues. Nonetheless, 
despite the many hurdles left to overcome in the production, evaluation and translation 
of ligand-directed liposomes towards clinical use in the context of cancer therapy, the 
utility of dual-ligand liposome technologies is promising. Ligand-directed liposomes 
have the potential to increase the selectivity of therapy, improving efficacy and reducing 
the potential for harmful side effects, and dual-ligand liposomes may additionally 
address intratumoral heterogeneity to overcome patient resistance to targeted therapies. 
The development of better methodologies and preclinical models to comprehensively 
characterize novel ligand-directed liposomes and better assess the likelihood of their 
performance in humans, including recapitulation of intratumoral heterogeneity, will 
likely improve translation of these nanotherapies from preclinical models through to the 
clinic.  
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